Patient-Reported Outcomes for Ocular Myasthenia Gravis: Response.
Patient-Reported Outcomes for Ocular Myasthenia Gravis: Response.
复制标题
DOI：
10.1097/wno.0000000000001512
复制
发表时间：
2023-12-01
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
我们赞赏Dr. Wong等人设计并初步验证了针对眼部重症肌无力（OMG）患者的疾病特异性患者报告结果（PRO）测量方法OMGRate的工作(1)。我们期待着回顾他们更大的多中心研究的结果，以验证OMGRate在OMG疾病谱系患者中的应用，以及他们对OMGRate对治疗反应性的评估。如果成功，OMGRate将是理解和衡量我们的OMG患者如何受到疾病和我们开出的治疗方法的影响的重要一步。它还将为未来的临床试验提供急需的疾病特异性PRO测量。
We applaud Dr. Wong et al for their work designing and preliminarily validating a disease-specific patientreported outcome (PRO) measure, OMGRate, for patients with ocular myasthenia gravis (OMG)(1). We look forward to reviewing the results from their larger, multicenter study to validate the OMGRate among patients across the OMG disease spectrum and their assessment of the responsiveness of the OMGRate to treatment. If successful, OMGRate would be an important step toward understanding and measuring how our patients with OMG are affected by disease and the treatments we prescribe. It would also provide a much needed, diseasespecific PRO measure for future clinical trials.